[go: up one dir, main page]

WO1997009315A1 - Carboxamides de pyrimidine et composes associes, et methodes de traitement d'etats inflammatoires - Google Patents

Carboxamides de pyrimidine et composes associes, et methodes de traitement d'etats inflammatoires Download PDF

Info

Publication number
WO1997009315A1
WO1997009315A1 PCT/US1996/015108 US9615108W WO9709315A1 WO 1997009315 A1 WO1997009315 A1 WO 1997009315A1 US 9615108 W US9615108 W US 9615108W WO 9709315 A1 WO9709315 A1 WO 9709315A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
trifluoromethyl
pyrimidine
carboxamide
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/015108
Other languages
English (en)
Inventor
Mark J. Suto
Mark E. Goldman
Leah M. Gayo
Lynn J. Ransone-Fong
Moorthy S. S. Palanki
Robert W. Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/581,473 external-priority patent/US5811428A/en
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Priority to AU71631/96A priority Critical patent/AU726522B2/en
Priority to JP9511471A priority patent/JPH11512399A/ja
Priority to EP96933070A priority patent/EP0850228A1/fr
Publication of WO1997009315A1 publication Critical patent/WO1997009315A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates generally to compounds that block intracellular signal transduction and activation of transcription factors, and to methods for preventing or treating immunoinflammatory and autoimmune diseases.
  • T-cells In certain autoimmune diseases or chronic inflammatory states, continuous activation of T-cells eventually leads to a self-perpetuating destruction of normal tissues or organs. This is caused by the induction of adhesion molecules, chemotaxis of leukocytes, activation of leukocytes and the production of mediators of inflammation. All of these events are regulated at the level of transcription for the production of new proteins, including cytokines.
  • cytokines The production of cytokines, as well as a number of other cellular regulators, is controlled by a family of proteins known as transcription factors (TFs). These transcription factors, when activated, bind to specific regions on the DNA and act as molecular switches or messengers to induce or upregulate gene expression.
  • TFs transcription factors
  • RNA transcripts The activation of these TFs is caused by a variety of external signals including physiological stress, infectious agents and other bioregulatory molecules.
  • a cascade of protein kinases and second messengers are induced which, in turn, result in the production of RNA transcripts.
  • the end result is the production of proinflammatory proteins via translation and processing ofthe RNA transcripts.
  • This activation system can, at times, be very robust. For example, a specific set of external signals could result in a single transcription factor to induce many proteins responsible for a given disease. Therefore, regulating this process by disrupting the production of activated TF(s) has the potential to attenuate the production of the associated pathological proteins, thereby halting or reversing the course ofthe disease.
  • NFKB and AP-1 Two transcription factors, NFKB and AP-1, have been shown to regulate the production of many proinflammatory cytokines and related proteins that are elevated in immunoinflammatory diseases. These TFs regulate interieukin- 1 (LL-1), interleukin-2 (IL-2), tumor necrosis factor- ⁇ (TNF ⁇ ), interleukin-6 (BL-6) and interleukin-8 (LL-8) levels in a variety of cell types.
  • IL-2 interleukin-2
  • TNF ⁇ tumor necrosis factor- ⁇
  • BL-6 interleukin-6
  • LL-8 interleukin-8
  • NFKB and other related complexes are involved in the rapid induction of genes whose products function in protective and proliferative responses upon exposure of cells to external stimuli.
  • AP-1 has a significant role in the regulation of interleukin-2 (LL-2) and tumor necrosis factor- ⁇ (TNF- ⁇ ) transcription during T-cell activation.
  • TNF- ⁇ and IL-1 are strong activators of collagenase, gelatinase and stromelysin gene expression, which require a single AP-1 binding site in the promoter region of these genes. Therefore, an inhibitor of NFKB and/or AP-1 activation would coordinately repress the activities of a series of proteinases.
  • cell adhesion molecules are also controlled by these TFs.
  • telomeres All of these proteins have been shown to play a role in diseases, including osteoarthritis, transplant rejection, ischemia, reperfusion injury, trauma, certain cancers and viral disorders, and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease, glomerulonephritis, lupus and juvenile diabetes.
  • autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease, glomerulonephritis, lupus and juvenile diabetes.
  • the role of these TFs is to act as a transducer for certain stimuli that lead to immune, inflammatory, and acute phase responses.
  • this invention is directed to compounds that block the activation of transcription factors (TFs), particularly NFKB and AP-1, and are believed to function through inhibition of a family of specific kinases.
  • TFs transcription factors
  • NFKB transcription factors
  • AP-1 binds to a family of specific kinases.
  • proinflammatory proteins including LL-1, LL-2, LL-8 and/or TNF ⁇ , which are responsible for tissue and organ damage associated with diseases such as rheumatoid arthritis, osteoarthritis, related autoimmune disorders and tissue rejection.
  • compounds of the present invention are useful in, for example, the prevention of organ and tissue rejection associated with transplantation.
  • the compounds of this invention also have utility in the prevention and/or treatment of immunoinflammatory and autoimmune diseases, as well as having general activity as anti-inflammatory agents.
  • a pharmaceutical composition containing one or more compounds of this invention in combination with a pharmaceutically or prophylactically acceptable carrier or diluent.
  • methods for preventing and/or treating inflammatory conditions by administering to a warm-blooded animal in need thereof an effective amount of a compound of this invention.
  • inflammatory conditions include both immunoinflammatory conditions and autoimmune diseases.
  • the compounds are preferably administered to the warm-blooded animal in the form of a pharmaceutical composition.
  • Figure 1 illustrates a reaction scheme for the synthesis of representative pyrimidine-containing compounds of this invention.
  • Figure 2 illustrates a reaction scheme for the synthesis of representative pyrazine-containing compounds of this invention.
  • Figure 3 illustrates the ability of a representative compound of this invention to inhibit the activation of NFKB and AP-1.
  • Figure 4 illustrates the ability of a representative compound of this invention to inhibit LL-2 and LL-8.
  • Figure 5 illustrates the ability of a representative compound of this invention to cause a dose-dependent suppression of alloantigen-induced PLN proliferation.
  • the compounds of this invention block activation of transcription factors (TFs), and thus have utility as anti-inflammatory agents in general, and in the prevention and/or treatment of a variety of conditions, including (but not limited to) immunoinflammatory and autoimmune diseases.
  • TFs transcription factors
  • the compounds are believed to function by inhibiting, at an early stage, transcription of deleterious proteins associated with such conditions or diseases. It is believed that this is achieved by inhibiting the kinase(s) that regulate the activation of TFs, such as NFKB and/or AP-1.
  • TFs transcription factors
  • structure (I) wherein A is C-R ⁇ when B is N, and A is N when B is C-Ri, and wherein Ri, R 2 , R,, R 5 and R ⁇ are as defined below.
  • structure (I) is a pyrimidine-containing compound having structure (II)
  • structure (I) is a pyrazine-containing compound having structure (III):
  • R 5 is selected from the following chemical moieties (i) through (iv):
  • R 7 is selected from hydrogen, -CH 3 and -CH 2 C ⁇ Hs.
  • Rg is selected from hydrogen and an unsubstituted or substituted Ci-galkyl, C ⁇ -naryl, C . ⁇ 2 aralkyl, C 3- ⁇ 2 heterocycle and a C .i6heterocyclealkyl.
  • the compounds of this invention further include pharmaceutically and prophylactically acceptable salts of compounds of structure (I).
  • Compounds of structure (I) may contain proton donating groups (e.g., a carboxylic acid group) and/or proton accepting groups (e.g., a group with a nitrogen atom having a free lone pair of electrons, such as an amine group), and the salts of compounds of structure (I) may be formed and utilized in the practice ofthe invention.
  • compounds ofthe invention may be in the form of a base addition salt (i.e., a salt of a proton donating group) or in the form of an acid addition salt (i.e., a salt of a proton accepting group), as well as the free acid or free base forms thereof.
  • the compounds of this invention also include those salts derived from inorganic bases such as the hydroxide or other salt of sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like, and organic bases such as substituted ammonium salts.
  • inorganic bases such as the hydroxide or other salt of sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like
  • organic bases such as substituted ammonium salts.
  • Ci-salkyl is a straight chain or branched, cyclic or non-cyclic, saturated or unsaturated carbon chain containing from 1 to 8 carbon atoms.
  • the Ci-galkyl is a fully saturated, straight chain alkyl selected from methyl, ethyl, n-propyl, n-butyl, n-pentyl and n-hexyl.
  • the Ci-galkyl is a fully saturated cyclic alkyl selected from (but not limited to) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methylenecyclopropyl and methylenecyclohexyl.
  • the Ci-galkyl is a fully saturated, branched alkyl selected from (but not limited to) isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl and isohexyl.
  • the Ci-galkyl is an unsaturated straight chain alkyl selected from (but not limited to) ethylenyl, propylenyl, 1-butenyl, 1 -pentenyl and 1-hexenyl.
  • a "C ⁇ -i ⁇ aryl" is an aromatic moiety containing from 6 to 12 carbon atoms.
  • the C ⁇ - ⁇ aryl is selected from (but not limited to) phenyl, tetralinyl, and napthalenyl.
  • the C 6 - ⁇ 2 aryl is phenyl.
  • a "C .i 2 aralkyl” is an arene containing from 7 to 12 carbon atoms, and has both aliphatic and aromatic units.
  • the C 7- ⁇ 2 aralkyl is selected from (but not limited to) benzyl, ethylbenzyl, propylbenzyl and isobutylbenzyl.
  • a "C 3- ⁇ 2 heterocycle” is a compound that contains a ring made up of more than one kind of atom, and which contains 3 to 12 carbon atoms.
  • the C 3 - ⁇ 2 heterocycle is selected from (but not limited to) pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, pyrrolidinyl, pyridinyl, pyrimidinyl and purinyl.
  • the C 3 . ⁇ 2 heterocycle includes the following structures:
  • A is a compound that contains a C3- ⁇ 2 heterocycle linked to a Ci-galkyl.
  • the C . ⁇ heterocyclealkyl is a methylene furan having the following structure:
  • Gn ⁇ heterocyclealkyl is a Ci-galkyl, C 7 .i 2 aralkyl, C 3 -i2heterocycle or
  • C-n ⁇ heterocyclealkyl having one or more hydrogens replaced with a substituent selected from halogen (including -F, -Cl, -Br and -I), -OH, -R, -OR, -COOH, -COOR, -COR, -CONH2, -NH 2 , -NHR, -NRR, -SH, -SR, -SOOR, -SO 3 R and -SOR, where each occurrence of R is independently selected from an unsubstituted or substituted C ⁇ .galkyl,
  • the substituted C ⁇ -8 alkyl is a Ci-ghaloalkyl including (but not limited to)
  • R2a is selected from halogen, an unsubstituted or substituted Ci-galkyl, C ⁇ -naryl, C 7 . ⁇ 2 aralkyl, C 3 -i2heterocycle or Gn ⁇ heterocyclealkyl,
  • R is independently selected from an unsubstituted or substituted Ci-galkyl, C ⁇ -i ⁇ aryl, C . ⁇ 2 aralkyl,
  • R2 is selected from -Cl, -F, -CN and -CF 3 .
  • R2 b is halogen, such as -Cl or -F.
  • R ⁇ is selected from hydrogen, halogen, an unsubstituted or substituted C ⁇ .galkyl, C ⁇ - ⁇ 2 aryl, C 7 -i2aralkyl, Cs- ⁇ heterocycle or -CN, -OR, -NHR, -NRR and -NRNCOR, wherein each occurrence of R is independently selected from an unsubstituted or substituted Ci-galkyl, C ⁇ -i 2 aryl, C 7 .i 2 aralkyl, C 3 .i 2 heterocycle or O-i ⁇ heterocyclealkyl as defined above.
  • R a is selected from hydrogen, -CH 3 , -CF 3 , -C 2 F 5 , -C 2 H 5 , -C 6 H 5 and
  • structure (III) above is selected from hydrogen, halogen, -CN, and an unsubstituted or substituted C ⁇ .galkyl, C ⁇ -naryl, C 7 . ⁇ 2 aralkyl, C 3 -i2heterocycle or
  • R ⁇ is selected from hydrogen, halogen, and an unsubstituted or substituted Ci-galkyl, including (but not limited to) a Ci-ghaloalkyl (such as -CF 3 and -C 2 F 5 ). In one embodiment, R ⁇ is selected from hydrogen, -Cl, -F, -CH 3 and -CF 3 .
  • Ri is selected from hydrogen, -CH 3 , -CF 3 and -C 2 H 5 .
  • the compounds of this invention have structure (II) above, wherein Ri is the chemical moiety (i).
  • the compounds disclosed herein have the following structure (IV):
  • R2,, R4a, R ⁇ , R7 and Rg are as defined above.
  • representative compounds of structure (IV) contain za, R- , R ⁇ , 7 and Rg moieties as identified in Table 1 below.
  • X, Y and Z are the same or different, and independently selected from hydrogen, - OH, -R, -OR, - COOH, -COOR, -COR, -CONH 2 , -NH 2 , -NHR,
  • R is independently selected from an unsubstituted or substituted C ⁇ . 8 alkyl, C ⁇ - ⁇ 2 aryl,
  • X, Y and Z are the same or different, and independently selected from -H, -Cl, -F, -CF3, -OH, -CH3 and -OCH 3 .
  • Rg is a 3,5- bis(trifluoromethyl)phenyl moiety or a 3-trifluoromethyl-5-halo-phenyl moiety.
  • the compounds have structure (II).
  • u is -CF 3 and R- & is -Cl.
  • Such compounds include (but are not limited to): 2-chloro-4-trifluoromethyl-5-N-(3 l ,5'- bistrifluoromethylphenyl)pyrimidine carboxamide; 2-chloro-4-trifluoromethyl-5-N-(3',5 I - dichlorophenyl)pyrimidine carboxamide; 2-chloro-4-trifluoromethyl-5-N-(4'- trifluoromethylphenyl)pyrimidine carboxamide; 2-chloro-4-trifluoromethyl-5-N- (phenyl)pyrimidine carboxamide; 2-chloro-4-trifluoromethyl-5-N-(cyclohexyl)pyrimidine carboxamide; 2-chloro-4-trifluoromethyl-5-N-(3',4',5'-trichloropheny
  • R 2 a is a moiety other than -Cl.
  • Such compounds include (but are not limited to): 2-fluoro-4- trifluoromethyl-5-N-(3',5'-bistrifluoromethyl)pyrimidine carboxamide, 5-(3',5'- bis(trifluoromethyl)phenacyl)-2-methoxy-4-trifluoromethylpyrimidine; 4-trifluoromethyl- 5-N-(3',5'-dichlorophenyl)pyrimidine carboxamide; 2-dimethylamino-4-trifluoromethyl- 5-N-(3',5 l -dichlorophenyl)pyrimidine carboxamide; 2-triethylammonium chloride-4- trifluoromethyl-5-N-(3',5'-dichlorophenyl)pyrimidine carboxamide; 2-cyano-4- trifluoromethyl-5-N-[3 ⁇ 5 ⁇ bistrifluoromethyl
  • R-j is -Cl and t, is a moiety other than -CF .
  • Such compounds include (but are not limited to): 5-N-(3',5'- bis(trifluoromethyl)phenyl)-2,4-dichloro-6-methyl-pyrimidine carboxamide; 2-chloro-4- methyl-5-N-(3 l ,5 , -(bistrifluoromethyl)phenyl)pyrimidine carboxamide; 2,4-dichloro-5-N- (S'.S'-bis ⁇ rifluoromethy benzy pyrimidine-S-carboxamide; and 2-chloro-4-phenyl-5-N- (3 ⁇ 5'-(bistrifluoromethyl)phenyl)pyrimidine carboxamide.
  • the compounds of this invention have structure (III) above.
  • Ri is selected from hydrogen, -CH3 and -CF 3 .
  • Such compounds include (but are not limited to) pyrazine-containing compounds which correspond to the pyrimidine-containing compounds disclosed above.
  • b is -Cl
  • ib is -CF 3
  • R 5 is a moiety of structure (i) above.
  • novel compounds of this invention do not include compounds of structure (IV) above where R 7 and Rg are both hydrogen, and where R-* * is selected from an unsubstituted, straight chain or branched, non-cyclic, saturated C 1 .3 alkyl (i.e., -CH 3 , -CH 2 CH 3 , -(CH 2 ) 2 CH 3 and -CH(CH 3 ) 2 ), -N(CH 3 ) 2 , -N(CH 2 CH 3 ) 2 and -OR, where R is as defined above.
  • novel compounds of structure (IV) are subject to the following provisos: (a) when R-* is -Cl and R ⁇ is -H, R- a is not -CF 3 , -Cl, -CH 3 or -C(CH 3 ) 3 , (b) when R2a is -Cl and both R4, and R ⁇ are -H, Rg is not -CH(CN)C ⁇ H 5 or -(CH 2 ) 5 CH 3 , and (c) when R ⁇ is -Cl and R 4a is -Cl, R ⁇ is not -Cl or
  • novel compounds of this invention also do not include compounds of structure (II) when R 5 is moiety (iii) and (a) R ⁇ a is -CH 3 , -OCH 3 or -N(CH 3 ) 2 , or (b) Rg is -H or -CH 3 .
  • novel compounds of structure (III) when R 5 is moiety (i) are subject to the following proviso: when R2b is -Cl, H, and Ri are not both hydrogen.
  • the compounds of this invention may be made by one skilled in organic synthesis by known techniques, as well as by the synthetic routes disclosed herein. For purpose of convenience, the compounds have been separated into pyrimidine-containing (structure (II)) and pyrazine-containing (structure (III)) compounds as set forth below.
  • the pyrimidine-containing compounds of this invention may be prepared as illustrated by the reaction scheme of Figure 1.
  • ⁇ -keto esters 1 are heated at elevated temperatures (75-110°C) with a mixture of urea and triethylorthoformate (or a substituted orthoformate) to provide ureido derivatives 2.
  • the 2-hydroxypyrimidine esters 3 may also be treated with a mild base, such as lithium hydroxide, sodium hydroxide or potassium carbonate to provide the corresponding acid 3A, which may then be converted with a chlorinating agent, such as phosphorous oxychloride or thionyl chloride in an inert solvent or neat at 25-75°C, to the acid chloride 5.
  • a chlorinating agent such as phosphorous oxychloride or thionyl chloride in an inert solvent or neat at 25-75°C
  • Compounds of structure 6 may be prepared using standard conditions known in the art by reacting the acid chloride 5 with an amine in the presence of a base, such as potassium carbonate or dimethylaminopyridine (DMAP), in a non-protic solvent, such as methylene chloride or EtOAc at 25-40°C, followed by standard workup.
  • a base such as potassium carbonate or dimethylaminopyridine (DMAP)
  • pyrimidine-containing compounds of this invention may also be made by the following combinatorial procedure.
  • Commercially available and/or readily synthesized amines, anilines and related compounds may be reacted with the acid chloride 5 in EtOAc in the presence of basic Amberlyst 21 resin. The reactions are quenched with 50 ⁇ L of water and the final products are obtained in the organic layer and concentrated. This procedure may be done in a 96 well (1 mL deep well) plate and the final products isolated as dry powders. TLC analysis is performed on each compound and indicates the purity, and GC MS and HPLC analysis demonstrates that the desired products are synthesized (mass spectral analysis, molecular weight) and are greater than 80% pure. By this method, eighty distinct pyrimidine-containing compounds may be routinely synthesized at the same time in one 96 well plate.
  • compound 4 may be reacted with various nucleophiles in an aprotic solvent and at ambient temperature to provide derivatives 7. These compounds can be hydrolyzed with base to yield compounds having structure 8.
  • Compounds of structure 8 can be converted to the acid chloride as described above, and reacted with various amines to give compounds having structure 9 using known conditions, including the combinatorial approach described above.
  • compounds of structure 7 can also be prepared by reacting the ⁇ -keto ester 1 in a sequential fashion with triethylorthoformate and acetic anhydride or N,N-dimethylformamide dimethyl acetal in DMF to give intermediate 10. Reacting intermediate 10 with a variety of amidines in alcoholic solvents provides intermediate 11 which, upon addition of base, provides compounds of structure 7.
  • Pyrazine-containing compounds of structure (III) may be prepared as illustrated by the reaction scheme of Figure 2.
  • the synthesis of these compounds may begin with readily available pyruvic acid derivatives 12. These compounds are condensed with commercially available 2-cyano-l,2-diamino-2-substituted ethenes 13 in an alcoholic solvent (such as MeOH) in the presence of an acid (such as HCl) at ambient temperatures (25-60°C) to provide the cyano pyrazines of structure 14.
  • the pyrazines may then be converted to the corresponding carboxylic acids 15 using a strong base such as sodium hydroxide in water, or a strong acid such as HCl, at elevated temperatures (70-110°C).
  • carboxylic acids may then be converted to 5-chloro-2-carbonyl acid chloride derivatives 16 using a chlorinating agent such as POCI3 or SOCI2.
  • a chlorinating agent such as POCI3 or SOCI2.
  • Treatment of 16 with various amines or anilines at ambient temperatures in an inert solvent such as EtOAc or CH2CI2 provides compounds of structure 17.
  • the carboxylic acids of structure 15 can also be converted to the hydroxy ester 18 by treatment with SOCl 2 and MeOH at a temperature of 25-60°C .
  • Compound 19 can also be converted to the acid chloride 16 using a mild base such as potassium carbonate in an a protic solvent such as MeOH, followed by treatment with a chlorinating agent such as oxalyl chloride in an inert solvent such as methylene chloride at ambient temperatures.
  • the pyrazine-containing compounds of this invention may also be synthesized by appropriate combinatorial techniques as described.
  • commercially available and/or readily synthesized amines, anilines and related compounds may be reacted with the acid chloride 16 in EtOAc in the presence of basic Amberlyst 21 resin.
  • the reactions are quenched with 50 ⁇ L of water and the final products are obtained in the organic layer and concentrated. This procedure may be done in a 96 well (1 mL deep well) plate and the final products isolated as dry powders.
  • TLC analysis is performed on each compound and indicates the purity, and GC and HPLC analysis demonstrates that the desired products are synthesized (mass spectral analysis, molecular weight) and are greater than 80% pure.
  • the compounds of this invention may be formulated for administration to a warm-blooded animal by a variety of techniques known to those skilled in the art.
  • the compound is in the form of a pharmaceutical composition for prophylactic or therapeutic use, and which contains at least one compound of this invention in combination with a pharmaceutically acceptable carrier or diluent.
  • the compound is present in the composition in an amount which, upon administration to the animal, is effective in preventing or treating the condition of interest.
  • the composition includes a compound of this invention in an amount ranging from 0.01 mg to 250 mg per dosage, depending upon the route of administration, and more preferably from 1 mg to 60 mg. Appropriate concentrations, dosages and modes of administration may be readily determined by one skilled in the art.
  • Suitable carriers or diluents are familiar to those skilled in the formulation field.
  • acceptable carrier or diluents include saline and sterile water, and may optionally include antioxidants, buffers, bacteriostats and other common additives.
  • the compositions of this invention may also be formulated as pills, capsules, granules or tablets which contain, in addition to the compound of this invention, diluents, dispersing and surface active agents, binders and lubricants.
  • the present invention provides methods for preventing or treating a variety of conditions. Such methods include administering a compound of this invention to a warm-blooded animal in need thereof in an amount sufficient to prevent or treat the condition.
  • Such methods include systemic administration of a compound of this invention, preferably in the form of a composition as disclosed above.
  • systemic administration includes oral and parental methods of administration.
  • suitable pharmaceutical compositions include powders, granules, pills, tablets and capsules, as well as liquids, syrups, suspensions and emulsions. These compositions may also include flavorants, preservatives, suspending, thickening and emulsifying agents, and other pharmaceutically acceptable additives.
  • the compounds of the present invention may be prepared in aqueous injectable solutions which may contain, in addition to the compound of this invention, buffers, antioxidants, bacteriostats and other additives commonly employed in such solutions.
  • aqueous injectable solutions which may contain, in addition to the compound of this invention, buffers, antioxidants, bacteriostats and other additives commonly employed in such solutions.
  • compounds ofthe present invention can be used to prevent or treat a wide variety of disorders, diseases and/or illnesses.
  • the compounds may be administered to a warm-blooded animal for prevention or treatment of rheumatoid arthritis, osteoarthritis, tissue and/or organ transplant rejection, sepsis, ARDS, asthma, trauma, oxidative stress, cell death, irradiation damage, ischemia, reperfusion, cancer, viral infection, and autoimmune diseases such as psoriasis, inflammatory bowel disease, glomerulonephritis, lupus, uveitis and chronic hepatitis.
  • Compounds of this invention may be screened by known and accepted techniques for their ability to function as prophylactically and/or therapeutically active agents.
  • the compounds may be evaluated in in vitro and/or in vivo assays indicative of the compound's antinflammatory and immunosuppressive properties.
  • such compounds may first be evaluated in a number of cell-based assays which determine the ability of a compound to prevent activation of NFKB and AP-l(5ee Example 56).
  • the compound's ability to attenuate cytokine levels (such as LL-2 and LL-8), which are known to be elevated in certain disease states, may be determined (see Example 57).
  • the compounds may then be evaluated in an appropriate animal model, including rodent models of inflammation and immunosuppression (see Example 58).
  • Examples 1-54 disclose the synthesis of representative compounds of this invention, as well as intermediates thereof;
  • Example 55 discloses the synthesis of representative compounds by combinational chemistry techniques;
  • Examples 56-57 disclose the ability of representative compounds of this invention to inhibit NFKB, AP-1 and cytokines;
  • Example 58 discloses the activity of a representative compound of this invention in both graft versus host disease and contact sensitivity models.
  • Example 5 2-CHLORO-4-TRIFLUOROMETHYL- 5-N-(BENZYL)PYRIMIDINE CARBOXAMIDE
  • the title compound was prepared as described above in Example 1, but employing benzylamine (0.09 g, 0.92 mmol) and the acid chloride (0.25 g, 1.0 mmol), resulting in a 78% yield; m.p. 152-153°C.
  • N-acyl-2-fluoro-5-nitroaniline (0.99 g, 5.00 mmol) was dissolved in EtOH (25 mL), and then 10% Pd/C (0.12 g) was added and the solution stirred under H 2 for 5 h.
  • the suspension was filtered through celite and the filtrate evaporated to dryness.
  • the resulting oil was chromatographed (SiO 2 , 1:3 hexanes/EtOAc) to provide 3-N-acyl-4-fluoro-aniline as a yellow oil.
  • the aniline derivative was then coupled to 2- chloro-4-trifluoromethylpyrimidine-5-carbonyl chloride as described in Example 1 to provide the title compound in a 47% yield; m.p. 126-127°C.
  • This compound was coupled to 2-chloro-4-trifluoromethylpyrimidine-5- carbonyl chloride as described and purified by chromatography (SiO ⁇ , 9:1 hexanes/EtOAc) to provide the title compound (15% yield) as a white foam; m.p. 102- 104°C.
  • the 2,4-dihydroxy-6-methyl pyrimidine-5-carboxylic acid was heated at reflux with POCI 3 .
  • the reaction mixture was concentrated and 2,4-dichloro-6- methylpyrimidine-5-carbonyl chloride was obtained by distillation (b.p. 70-80°C, 1.5 mm/Hg).
  • ETHYL UREIDOMETHYLE ⁇ E ACETOACETATE A mixture of ethyl acetoacetate (200 g, 1.54 mol), urea (105 g, 1.54 mole) and triethyl orthoformate (228 g, 1.54 mol) was heated at 140°C under ⁇ 2 for 22 h. The reaction mixture was cooled and filtered to provide the title compound in a 51% yield (156 g); m.p. 173-174°C.
  • Example 18 ETHYL UREIDOMETHYLENE BENZOYLACETATE
  • the title compound was prepared as described in Example 17, but employing ethyl benzoylacetate (30 g, 156 mmol), resulting in a yield of 21% (12 g); m.p. 124-126°C.
  • Example 26 2-CHLORO-4-PHENYLPYRIMIDINE-5-CARBONYL CHLORIDE The compound was prepared as described above in Example 25, but employing 2-chloro-4-phenylpyrimidine-5-carboxylic acid (3.8 g, 14 mmol), resulting in a yield of53 %; m.p. 42°C.
  • the desired acid chloride was obtained from 2,4-bis(trifluoromethyl)- pyrimidine-5-carboxylic acid in a manner similar to that described in Example 25 in a yield of 44%; b.p. 105°C (1.5 mm/Hg); 1HNMR (CDC1 3 ) ⁇ 9.12 (s, IH).
  • Example 45 2-[N-( 1 -AMINOCITRACONAMIDE)]-4-TRIFLUOROMETHYL- 5- ⁇ sf-(3 , ,5'-DICHLOROPHENYL)]-PYRIMIDINE-5-CARBOXAMIDE
  • a solution of 2-hydrazino-4-trifluoromethyl-5-[N-(3 l ,5'- dichlorophenyl)pyrimidine carboxamide (0.08 g, 0.21 mmol) and citraconic anhydride (0.024 g, 0.21 mmol) in CHC1 3 (2.1 mL) was heated at reflux under N 2 for 24 h. The solution was concentrated and chromatographed (Si ⁇ 2, 33% EtOAc/hexane) to afford the title compound (0.06 g, 62% yield); m.p. 182-183°C.
  • Example 49 2-CHLORO-5-N-(BISTRIFLUOROMETHYL ANILINE) PYRAZINE CARBOXAMIDE
  • the title compound was prepared in a yield of 51% (0.08 g) using the same procedure as outlined in Example 1, except substituting 2-chloro-5-pyrazine carbonyl chloride (0.1 g, 0.57 mmol.) in place of the pyrimidine carbonyl chloride; m.p. 101-102°C.
  • Example 52 2-FLUORO-4-TRIFLUOROMETHYL- 5-PYRIMIDINE CARBONYL CHLORIDE
  • the title compound was prepared as described in Example 25, but employing a solution of 2-fluoro-4-trifluoromethylpyrimidine-5-carboxylic acid (1.5 g, 7.1 mmol) and oxalyl chloride (1.0 g, 8 mmol), DMF (2 drops) in CH 2 C1 2 (30 mL) resulted in a 75% yield (1.2 g); 1H NMR (CDC1 3 ) ⁇ 9.42 (s, IH).
  • Example 53 2-FLUORC)-4-TRIF UOROMETHYL-5-N-[3 , ,5 , -BLS(TRIFLUOROMETHYL)PHENYL]
  • PYRIMIDINE CARBOXAMIDE The title compound was prepared as described in Example 1, but employing a solution of 2-fluoro-4-trifluoromethylpyrimidine-5-carbonyl chloride (0.05 g, 0.22 mmol) and 3,5-bis(trifluoromethyl)aniline (45 mg, 0.2 mmol) in EtOAc (2 mL) resulted in a 22% yield (0.02 g); m.p. 133-135°C.
  • 5-PYRIMIDINE CARBONYL CHLORIDE The title compound was prepared as described in Example 25, but employing a solution of 2-chloro-4-trifluoromethylpyrimidine-5-carboxylic acid (1.5 g, 7.1 mmol) and oxalyl chloride (1.0 g, 8 mmol) in CH 2 C1 2 (30 mL) resulted in a 70% yield (l.lg); 1H NMR (CDC1 3 ) ⁇ 9.31 (s, IH).
  • NFKB ASSAY Stable human Jurkat T-cells containing an NFKB binding site (from the
  • MHC promoter fused to a minimal SV-40 promoter driving luciferase expression were used in this experiment.
  • Cells were split to 3 x 10 5 cells/mL every 2-3 days (cell concentration should not exceed 1 x IO 6 cells/mL to keep the cells proliferating in log phase). These cells were counted, resuspended in fresh medium containing 10% Serum- Plus at a density of 1 x IO 6 cells/mL and plated in 96 well round bottom plates (200 ⁇ L per well) 18 hours prior to starting the experiment.
  • the assay was run as described above for NFKB except stable Jurkat T-cells were used that contained a collagenase promoter driving luciferase expression.
  • concentration of PMA used was 5 ng mL.
  • the murine popliteal lymph node (PLN) assay is a graft vs. host model that predicts activity of compounds in blocking human transplant rejection.
  • the delayed- type hypersensitivity response to oxazolone is a standard contact sensitivity model. Both of these models are used routinely to evaluate compounds that are used clinically. For example, cyclosporin and cyclophosphamide are active in these models and are used clinically (Morris et al., Transplantation Proceedings 22(Suppl. 1): 110-112, 1990).
  • Spleens were removed from donor BALB/c mice and splenocytes were isolated then irradiated (3,000 rads) to prevent donor cell proliferation. After washing and adjusting cell density, 2.5x10 6 cells were injected subcutaneously into the left hind footpad of C3H mice. On day 4, the mice were sacrificed and left popliteal lymph nodes (PLNs) were weighed .
  • PPNs left popliteal lymph nodes
  • Example 1 The compound of Example 1, 2-chloro-4-trifluoromethyl-5-N-(3',5'- bistrifluoromethylphenyl)pyrimidine carboxamide, was administered once daily by intraperitoneal injection beginning one day before footpad injection (day 0) through day 4.
  • the compound was suspended, immediately prior to use, at a concentration of 5 mg/mL in 0.25% methyl cellulose (Sigma) using a glass-teflon homogenizer.
  • appropriate dilutions of the stock solution were made so that 0.1 mL/10 g body weight was administered by intraperitoneal injection.
  • Cyclophosphamide 50 (i.p.) 0.08 ⁇ 0.01 ⁇ 0.001
  • test compound (30 mg/kg i.p.) and cyclophosphamide (50 mg/kg i.p.) significantly attenuated the delayed-type response to oxazolone by 56% and 73%, respectively.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés présentant une utilité comme agents anti-inflammatoires en général, et plus spécifiquement, pour la prévention et/ou le traitement des maladies immuno-inflammatoires et auto-immunes. Ces composés sont des composés contenant de la pyrimidine ou de la pyrazine, et dans un mode de réalisation, sont des carboxyamides de ces substances. Sont décrites également des méthodes de prévention et/ou de traitement d'états inflammatoires par l'administration à un animal ayant besoin d'un tel traitement d'une quantité efficace d'un composé de cette invention, de préférence sous la forme d'une préparation pharmaceutique.
PCT/US1996/015108 1995-09-01 1996-08-30 Carboxamides de pyrimidine et composes associes, et methodes de traitement d'etats inflammatoires Ceased WO1997009315A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU71631/96A AU726522B2 (en) 1995-09-01 1996-08-30 Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
JP9511471A JPH11512399A (ja) 1995-09-01 1996-08-30 ピリミジンカルボキサミドおよび関連化合物ならびに炎症状態を処置するための方法
EP96933070A EP0850228A1 (fr) 1995-09-01 1996-08-30 Carboxamides de pyrimidine et composes associes, et methodes de traitement d'etats inflammatoires

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US310995P 1995-09-01 1995-09-01
US60/003,109 1995-12-18
US08/581,473 US5811428A (en) 1995-12-18 1995-12-18 Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US08/581,473 1995-12-18

Publications (1)

Publication Number Publication Date
WO1997009315A1 true WO1997009315A1 (fr) 1997-03-13

Family

ID=26671336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/015108 Ceased WO1997009315A1 (fr) 1995-09-01 1996-08-30 Carboxamides de pyrimidine et composes associes, et methodes de traitement d'etats inflammatoires

Country Status (5)

Country Link
EP (1) EP0850228A1 (fr)
JP (1) JPH11512399A (fr)
AU (1) AU726522B2 (fr)
CA (1) CA2230894A1 (fr)
WO (1) WO1997009315A1 (fr)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001441A1 (fr) * 1997-07-01 1999-01-14 Signal Pharmaceuticals, Inc. Analogues de quinazoline et composes associes et methodes pour traiter les troubles inflammatoires
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
WO2000073279A1 (fr) * 1999-05-31 2000-12-07 F. Hoffmann-La Roche Ag Derives de 4-phenyle-pyrimidine
WO2001021206A1 (fr) * 1999-09-17 2001-03-29 Suntory Limited MOYENS DE PREVENTION OU REMEDES CONTRE LA MYOCARDITE, LA CARDIOMYOPATHIE DILATEE ET L'INSUFFISANCE CARDIAQUE CONTENANT DES INHIBITEURS NF-λB EN TANT QU'INGREDIENT ACTIF
EP1018514A4 (fr) * 1998-07-22 2001-05-30 Suntory Ltd INHIBITEURS DE NF-$g(k)B CONTENANT DES DERIVES D'INDANE EN TANT QU'INGREDIENT ACTIF
WO2000073278A3 (fr) * 1999-05-31 2001-07-05 Hoffmann La Roche Derives de 5-phenyle-pyrimidine
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
WO2003020278A1 (fr) * 2001-08-30 2003-03-13 Novartis Ag Inhibiteurs de cysteine protease ayant une structure de 2-cyano-4-amino-pyrimidine et une activite d'inhibition de cathepsine k, pour traiter les inflammations et autres troubles
US6596746B1 (en) 1999-04-15 2003-07-22 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6656904B2 (en) 1998-07-10 2003-12-02 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
WO2004000819A1 (fr) * 2002-06-24 2003-12-31 Astrazeneca Ab Nouvelle utilisation de pyrimidine - ou triazine- 2-carbonitiles destines au traitement de maladies liees a l'activite de protease a cysteine et nouveaux derives de pyrimidine-2-carbonitile
WO2004018434A1 (fr) * 2002-08-21 2004-03-04 Glaxo Group Limited Composes de pyrimidine
WO2004018433A1 (fr) * 2002-08-21 2004-03-04 Glaxo Group Limited Derives de pyrimidine et leur utilisation en tant que modulateurs cb2
WO2004020441A1 (fr) * 2002-08-30 2004-03-11 Novartis Ag Derives d'hetereoaryle nitrile
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
EP1351691A4 (fr) * 2000-12-12 2005-06-22 Cytovia Inc 2-aryl-4-arylaminopyrimidines substituees et analogues en tant qu'activateurs de caspases et qu'inducteurs d'apoptose, et utilisation associee
WO2005074939A1 (fr) * 2004-02-03 2005-08-18 Glaxo Group Limited Combinaison de modulateurs du cb2 et d'inhibiteurs de la pde4 utilisee en medecine
WO2005075440A1 (fr) * 2004-02-03 2005-08-18 Glaxo Group Limited 2-(phenylamino)-pyrimidin-5-amides utilises comme modulateurs des recepteurs cannabinoides 2 dans le traitement de troubles immuns ou inflammatoires
WO2005080350A1 (fr) * 2004-02-23 2005-09-01 Glaxo Group Limited Derives de pyrimidine utilises comme modulateurs des recepteurs cannabinoides
WO2005080349A1 (fr) * 2004-02-24 2005-09-01 Glaxo Group Limited Derives de pyrimidine
EP1487796A4 (fr) * 2002-03-28 2005-11-16 Neurogen Corp Biarylamides substitues en tant que modulateurs du recepteur c5a
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7148225B2 (en) 2002-03-28 2006-12-12 Neurogen Corporation Substituted biaryl amides as C5A receptor modulators
US7205307B2 (en) 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
US7226927B2 (en) 2000-12-12 2007-06-05 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US7626042B2 (en) 2002-06-06 2009-12-01 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
WO2010113834A1 (fr) 2009-03-30 2010-10-07 アステラス製薬株式会社 Composé pyrimidine
US8067589B2 (en) 2007-02-26 2011-11-29 Pfizer Inc Heterocyclic compounds useful in treating diseases and conditions
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2583678A2 (fr) 2004-06-24 2013-04-24 Novartis Vaccines and Diagnostics, Inc. Immunopotentiateurs de petites molécules et dosages pour leur détection
US8952027B2 (en) 2008-04-16 2015-02-10 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US9359308B2 (en) 2011-11-23 2016-06-07 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
WO2017122209A3 (fr) * 2016-01-12 2017-11-02 Yeda Research And Development Co. Ltd. Inhibiteurs de nf-kb
US10391094B2 (en) 2010-11-07 2019-08-27 Impact Biomedicines, Inc. Compositions and methods for treating myelofibrosis
US10933052B2 (en) 2017-11-17 2021-03-02 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2487891A1 (fr) * 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Inhibiteurs de l'activation de ap-1 et de nfat
US8580805B2 (en) * 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE489416A (fr) *
US3517009A (en) * 1968-04-05 1970-06-23 American Home Prod 4-hydroxy(lower)alkylamino-n,2-disubstituted-5-pyrimidinecarboxamides
US3517010A (en) * 1968-04-05 1970-06-23 American Home Prod 5-acetamido-4-pyrimidinecarboxylic acids and related compounds
FR2139411A5 (fr) * 1971-05-12 1973-01-05 Ciba Geigy Ag
DE2906461A1 (de) * 1978-02-21 1979-08-23 Delalande Sa Pyrimidin-5-carbonsaeureamid-derivate, verfahren zu ihrer herstellung und solche derivate enthaltende arzneimittel
DE3205638A1 (de) * 1982-02-17 1983-08-25 Hoechst Ag, 6230 Frankfurt Trisubstituierte pyrimidin-5-carbonsaeuren und deren derivate, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
JPS63107966A (ja) * 1986-05-22 1988-05-12 Fujisawa Pharmaceut Co Ltd ピリミジン誘導体
JPS63198670A (ja) * 1987-02-13 1988-08-17 Daicel Chem Ind Ltd ピリミジン−５−カルボキサミド誘導体及び植物成長抑制剤
JPH01180805A (ja) * 1988-01-05 1989-07-18 Daicel Chem Ind Ltd 除草剤組成物
JPH01180804A (ja) * 1988-01-05 1989-07-18 Daicel Chem Ind Ltd 除草剤組成物
EP0569912A1 (fr) * 1992-05-15 1993-11-18 Hoechst Schering AgrEvo GmbH Pyrimidino-5-carboxanilides 4-alkyl-substituées, procédé pour leur préparation, compositions les contenant et leur utilisation comme fongicides
WO1995025723A1 (fr) * 1994-03-18 1995-09-28 Agrevo Uk Limited Derives d'anilide utilises comme fongicides

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE489416A (fr) *
US3517009A (en) * 1968-04-05 1970-06-23 American Home Prod 4-hydroxy(lower)alkylamino-n,2-disubstituted-5-pyrimidinecarboxamides
US3517010A (en) * 1968-04-05 1970-06-23 American Home Prod 5-acetamido-4-pyrimidinecarboxylic acids and related compounds
FR2139411A5 (fr) * 1971-05-12 1973-01-05 Ciba Geigy Ag
DE2906461A1 (de) * 1978-02-21 1979-08-23 Delalande Sa Pyrimidin-5-carbonsaeureamid-derivate, verfahren zu ihrer herstellung und solche derivate enthaltende arzneimittel
DE3205638A1 (de) * 1982-02-17 1983-08-25 Hoechst Ag, 6230 Frankfurt Trisubstituierte pyrimidin-5-carbonsaeuren und deren derivate, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
JPS63107966A (ja) * 1986-05-22 1988-05-12 Fujisawa Pharmaceut Co Ltd ピリミジン誘導体
JPS63198670A (ja) * 1987-02-13 1988-08-17 Daicel Chem Ind Ltd ピリミジン−５−カルボキサミド誘導体及び植物成長抑制剤
JPH01180805A (ja) * 1988-01-05 1989-07-18 Daicel Chem Ind Ltd 除草剤組成物
JPH01180804A (ja) * 1988-01-05 1989-07-18 Daicel Chem Ind Ltd 除草剤組成物
EP0569912A1 (fr) * 1992-05-15 1993-11-18 Hoechst Schering AgrEvo GmbH Pyrimidino-5-carboxanilides 4-alkyl-substituées, procédé pour leur préparation, compositions les contenant et leur utilisation comme fongicides
WO1995025723A1 (fr) * 1994-03-18 1995-09-28 Agrevo Uk Limited Derives d'anilide utilises comme fongicides

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 109, no. 19, 1988, Columbus, Ohio, US; abstract no. 170451j, page 726; column 2; XP002021900 *
CHEMICAL ABSTRACTS, vol. 110, no. 9, 1989, Columbus, Ohio, US; abstract no. 75558m, page 660; column 2; XP002021901 *
CHEMICAL ABSTRACTS, vol. 112, no. 5, 1990, Columbus, Ohio, US; abstract no. 2621h, page 267; XP002021902 *
CHEMICAL ABSTRACTS, vol. 112, no. 5, 1990, Columbus, Ohio, US; abstract no. 50609g, page 269; XP002021903 *
CHEMICAL ABSTRACTS, vol. 88, no. 3, 1978, Columbus, Ohio, US; abstract no. 22973p, page 644; column 1; XP002021907 *
P.DOSTERT ET AL.: "STUDIES ON THE NEUROLEPTIC BENZAMIDES", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRYCHIMICA THERAPEUTICA., vol. 17, no. 5, 1982, PARIS FR, pages 437 - 444, XP002021899 *

Cited By (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001441A1 (fr) * 1997-07-01 1999-01-14 Signal Pharmaceuticals, Inc. Analogues de quinazoline et composes associes et methodes pour traiter les troubles inflammatoires
US5939421A (en) * 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US6150372A (en) * 1997-07-01 2000-11-21 Signal Pharmaceuticals, Inc. Pyridopyrimidine analogs and related compounds and methods for treating inflammatory conditions
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6458813B1 (en) 1997-11-07 2002-10-01 Amgen Inc. Substituted pyridine compounds and methods of use
US6184237B1 (en) 1997-11-07 2001-02-06 Amgen Inc. Substituted pyridine compounds and methods of use
US6333341B1 (en) 1997-11-07 2001-12-25 Amgen Inc. Substituted pyridine compounds and methods of use
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6884769B1 (en) 1998-07-10 2005-04-26 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating hair growth
US6838252B2 (en) 1998-07-10 2005-01-04 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating hair growth
US7175994B2 (en) 1998-07-10 2007-02-13 Osteoscreen Ip, Llc Inhibitors of proteasomal activity for stimulating hair growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US7223554B2 (en) 1998-07-10 2007-05-29 Osteoscreen, Ltd. Inhibitors of proteasomal activity for stimulating hair growth
WO2000002548A3 (fr) * 1998-07-10 2003-04-17 Osteoscreen Inhibiteurs d'activite proteasomique pour la stimulation de la croissance osseuse et capillaire
US6958220B2 (en) 1998-07-10 2005-10-25 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating hair growth
US6656904B2 (en) 1998-07-10 2003-12-02 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
EP1018514A4 (fr) * 1998-07-22 2001-05-30 Suntory Ltd INHIBITEURS DE NF-$g(k)B CONTENANT DES DERIVES D'INDANE EN TANT QU'INGREDIENT ACTIF
US6734180B1 (en) 1998-07-22 2004-05-11 Daiichi Suntory Pharma Co., Ltd. NF-κB inhibitor comprising an indan derivative as an active ingredient
US9382219B2 (en) 1999-04-15 2016-07-05 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6979694B2 (en) 1999-04-15 2005-12-27 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6596746B1 (en) 1999-04-15 2003-07-22 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US8993567B2 (en) 1999-04-15 2015-03-31 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7091223B2 (en) 1999-04-15 2006-08-15 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US8716323B2 (en) 1999-04-15 2014-05-06 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7153856B2 (en) 1999-04-15 2006-12-26 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7189854B2 (en) 1999-04-15 2007-03-13 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
RU2243221C2 (ru) * 1999-05-31 2004-12-27 Ф.Хоффманн-Ля Рош Аг Производные 4-фенилпиримидина и фармацевтическая композиция
RU2244710C2 (ru) * 1999-05-31 2005-01-20 Ф.Хоффманн-Ля Рош Аг Производные 5-фенилпиримидина и фармацевтическая композиция
WO2000073279A1 (fr) * 1999-05-31 2000-12-07 F. Hoffmann-La Roche Ag Derives de 4-phenyle-pyrimidine
US6756380B1 (en) 1999-05-31 2004-06-29 Hoffmann-La Roche Inc. 5-phenyl-pyrimidine derivatives
WO2000073278A3 (fr) * 1999-05-31 2001-07-05 Hoffmann La Roche Derives de 5-phenyle-pyrimidine
US6274588B1 (en) 1999-05-31 2001-08-14 Hoffmann-La Roche Inc. 4-phenyl-pyrimidine derivatives
WO2001021206A1 (fr) * 1999-09-17 2001-03-29 Suntory Limited MOYENS DE PREVENTION OU REMEDES CONTRE LA MYOCARDITE, LA CARDIOMYOPATHIE DILATEE ET L'INSUFFISANCE CARDIAQUE CONTENANT DES INHIBITEURS NF-λB EN TANT QU'INGREDIENT ACTIF
US6703421B1 (en) 1999-09-17 2004-03-09 Daiichi Suntory Pharma Co., Ltd. Methods of using phenylmethylbenzoquinone and hydroquinone compounds for treatment of myocarditis, dilated cardiomyopathy and heart failure
EP1351691A4 (fr) * 2000-12-12 2005-06-22 Cytovia Inc 2-aryl-4-arylaminopyrimidines substituees et analogues en tant qu'activateurs de caspases et qu'inducteurs d'apoptose, et utilisation associee
US7226927B2 (en) 2000-12-12 2007-06-05 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
KR100629834B1 (ko) * 2001-08-30 2006-09-29 노파르티스 아게 염증 및 다른 질병의 치료를 위한2-시아노-4-아미노-피리미딘 구조 및 카텝신 ｋ 저해활성을 갖는 시스테인 프로테아제 저해제
WO2003020278A1 (fr) * 2001-08-30 2003-03-13 Novartis Ag Inhibiteurs de cysteine protease ayant une structure de 2-cyano-4-amino-pyrimidine et une activite d'inhibition de cathepsine k, pour traiter les inflammations et autres troubles
US7112589B2 (en) 2001-08-30 2006-09-26 Novartis Ag Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
AU2002333758B2 (en) * 2001-08-30 2006-01-19 Novartis Ag Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases
US7205307B2 (en) 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
US7148225B2 (en) 2002-03-28 2006-12-12 Neurogen Corporation Substituted biaryl amides as C5A receptor modulators
EP1487796A4 (fr) * 2002-03-28 2005-11-16 Neurogen Corp Biarylamides substitues en tant que modulateurs du recepteur c5a
US7626042B2 (en) 2002-06-06 2009-12-01 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
WO2004000819A1 (fr) * 2002-06-24 2003-12-31 Astrazeneca Ab Nouvelle utilisation de pyrimidine - ou triazine- 2-carbonitiles destines au traitement de maladies liees a l'activite de protease a cysteine et nouveaux derives de pyrimidine-2-carbonitile
US7125881B2 (en) 2002-06-24 2006-10-24 Astrazeneca Ab Use of pyrimidine—or triazine—2 carbonitiles for treating diseases associated with cysteine prostease activity and novel pyrimidine-2-carbonitile derivatives
WO2004018433A1 (fr) * 2002-08-21 2004-03-04 Glaxo Group Limited Derives de pyrimidine et leur utilisation en tant que modulateurs cb2
US7635701B2 (en) 2002-08-21 2009-12-22 Glaxo Group Limited Pyrimidine derivatives and their use as CB2 modulators
EP1736470A3 (fr) * 2002-08-21 2007-04-04 Glaxo Group Limited Dérivés de pyrimidine comme modulateurs du récepteur cannabinoide CB2
WO2004018434A1 (fr) * 2002-08-21 2004-03-04 Glaxo Group Limited Composes de pyrimidine
EP1878725A2 (fr) 2002-08-21 2008-01-16 Glaxo Group Limited Dérivés de la pyrimidine et leur utilisation comme modulateurs de CB2
EP1878725A3 (fr) * 2002-08-21 2008-01-30 Glaxo Group Limited Dérivés de la pyrimidine et leur utilisation comme modulateurs de CB2
EA010130B1 (ru) * 2002-08-21 2008-06-30 Глэксо Груп Лимитед (тетрагидропиран-4-илметил)амид 2-(2,4-дихлорфениламино)-4-трифторметилпиримидин-5-карбоновой кислоты, фармацевтическая композиция, содержащая его, и способ лечения человека или животного, страдающего от состояния, которое опосредуется активностью каннабиноидных рецепторов 2
EA012703B1 (ru) * 2002-08-21 2009-12-30 Глэксо Груп Лимитед Производные пиримидина и их применение в качестве модуляторов cb2
US7544688B2 (en) 2002-08-30 2009-06-09 Novartis Ag Hetereoaryl nitrile derivatives
US7820818B2 (en) 2002-08-30 2010-10-26 Novartis Ag Heteroaryl nitrile derivatives
WO2004020441A1 (fr) * 2002-08-30 2004-03-11 Novartis Ag Derives d'hetereoaryle nitrile
WO2005074939A1 (fr) * 2004-02-03 2005-08-18 Glaxo Group Limited Combinaison de modulateurs du cb2 et d'inhibiteurs de la pde4 utilisee en medecine
WO2005075440A1 (fr) * 2004-02-03 2005-08-18 Glaxo Group Limited 2-(phenylamino)-pyrimidin-5-amides utilises comme modulateurs des recepteurs cannabinoides 2 dans le traitement de troubles immuns ou inflammatoires
WO2005080350A1 (fr) * 2004-02-23 2005-09-01 Glaxo Group Limited Derives de pyrimidine utilises comme modulateurs des recepteurs cannabinoides
WO2005080349A1 (fr) * 2004-02-24 2005-09-01 Glaxo Group Limited Derives de pyrimidine
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
EP2583678A2 (fr) 2004-06-24 2013-04-24 Novartis Vaccines and Diagnostics, Inc. Immunopotentiateurs de petites molécules et dosages pour leur détection
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
US8067589B2 (en) 2007-02-26 2011-11-29 Pfizer Inc Heterocyclic compounds useful in treating diseases and conditions
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US9579320B2 (en) 2008-04-16 2017-02-28 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8937070B2 (en) 2008-04-16 2015-01-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8952027B2 (en) 2008-04-16 2015-02-10 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8501944B2 (en) 2008-04-16 2013-08-06 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US11414410B2 (en) 2008-04-16 2022-08-16 Alexion Pharmaceuticals, Inc. Inhibitors of protein kinases
US10533001B2 (en) 2008-04-16 2020-01-14 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US9868729B2 (en) 2008-04-16 2018-01-16 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8524727B2 (en) 2009-03-30 2013-09-03 Astellas Pharma Inc. Pyrimidine compound
WO2010113834A1 (fr) 2009-03-30 2010-10-07 アステラス製薬株式会社 Composé pyrimidine
US10391094B2 (en) 2010-11-07 2019-08-27 Impact Biomedicines, Inc. Compositions and methods for treating myelofibrosis
US9359308B2 (en) 2011-11-23 2016-06-07 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
WO2017122209A3 (fr) * 2016-01-12 2017-11-02 Yeda Research And Development Co. Ltd. Inhibiteurs de nf-kb
US10933052B2 (en) 2017-11-17 2021-03-02 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders

Also Published As

Publication number Publication date
EP0850228A1 (fr) 1998-07-01
CA2230894A1 (fr) 1997-03-13
AU726522B2 (en) 2000-11-09
JPH11512399A (ja) 1999-10-26
AU7163196A (en) 1997-03-27

Similar Documents

Publication Publication Date Title
EP0850228A1 (fr) Carboxamides de pyrimidine et composes associes, et methodes de traitement d'etats inflammatoires
US5811428A (en) Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
AU726058B2 (en) Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en) Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
KR100565439B1 (ko) 신규 피리다진 유도체 및 이를 유효성분으로 하는 의약
US5852028A (en) Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
EP1633726A1 (fr) Derives de pyrimidine utiles pour le traitement des maladies mediees par crth2
WO2003030909A1 (fr) 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
JP2009221233A (ja) 新規化合物
NO851877L (no) Nye terapeutisk virksomme pyrimidinforbindelser og fremgangsmaater til deres fremstilling.
PL170373B1 (pl) Sposób wytwarzania nowych, podstawionych 5-arylopirymidyn PL PL PL
US7317014B2 (en) Bio-active pyrimidine molecules
AU2006335967B2 (en) Novel heterocycles
Goto et al. Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors
CA2207100C (fr) Derives pyrimidiniques
AU2009208712B2 (en) Novel heterocycles
US5883092A (en) Pyrimidine derivatives as endothelin antagonists
EP1896476A2 (fr) Nouveaux dérivés de pyrazolopyrimidinone
OKAMOTO et al. Synthesis of 2-Substituted-6-amino-4, 5-dihydropyrimidine
岡本義久 et al. Synthesis of 2-Substituted-6-amino-4, 5-dihydropyrimidine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2230894

Country of ref document: CA

Ref country code: CA

Ref document number: 2230894

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1997 511471

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996933070

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996933070

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996933070

Country of ref document: EP